1089 related articles for article (PubMed ID: 25372357)
1. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
[TBL] [Abstract][Full Text] [Related]
2. Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.
Eriksson D; Karlsson L; Eklund O; Dieperink H; Honkanen E; Melin J; Selvig K; Lundberg J
BMC Health Serv Res; 2017 Aug; 17(1):560. PubMed ID: 28806944
[TBL] [Abstract][Full Text] [Related]
3. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
[TBL] [Abstract][Full Text] [Related]
4. Mortality risk in patients with autosomal dominant polycystic kidney disease.
Mladsi D; Zhou X; Mader G; Sanon M; Wang J; Barnett C; Willey C; Seliger S
BMC Nephrol; 2024 Feb; 25(1):56. PubMed ID: 38365638
[TBL] [Abstract][Full Text] [Related]
5. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease.
Blanchette CM; Iorga ŞR; Altan A; Seare JG; Fan Y; Rossetti S; Gutierrez B
J Health Econ Outcomes Res; 2014; 2(1):63-74. PubMed ID: 37664083
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
[TBL] [Abstract][Full Text] [Related]
8. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
Knight T; Schaefer C; Krasa H; Oberdhan D; Chapman A; Perrone RD
Clinicoecon Outcomes Res; 2015; 7():123-32. PubMed ID: 25759590
[TBL] [Abstract][Full Text] [Related]
9. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
[TBL] [Abstract][Full Text] [Related]
10. Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.
Panizo N; Goicoechea M; García de Vinuesa S; Arroyo D; Yuste C; Rincón A; Verdalles U; Ruiz-Caro C; Quiroga B; Luño J
Nefrologia; 2012; 32(2):197-205. PubMed ID: 22425799
[TBL] [Abstract][Full Text] [Related]
11. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.
Perrone RD; Ruthazer R; Terrin NC
Am J Kidney Dis; 2001 Oct; 38(4):777-84. PubMed ID: 11576881
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.
Korves C; Eldar-Lissai A; McHale J; Lafeuille MH; Hwa Ong S; Sheng Duh M
J Med Econ; 2012; 15(5):925-37. PubMed ID: 22502902
[TBL] [Abstract][Full Text] [Related]
13. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.
McGovern AP; Jones S; van Vlymen J; Saggar AK; Sandford R; de Lusignan S
BMC Nephrol; 2014 Nov; 15():182. PubMed ID: 25412767
[TBL] [Abstract][Full Text] [Related]
14. NOS3 tagSNPs does not modify the chronic kidney disease progression in autosomal dominant polycystic kidney disease.
Ramanathan G; Periyasamy S; Lakkakula BV
Nephrology (Carlton); 2014 Sep; 19(9):537-41. PubMed ID: 24824375
[TBL] [Abstract][Full Text] [Related]
15. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.
Spithoven EM; Kramer A; Meijer E; Orskov B; Wanner C; Caskey F; Collart F; Finne P; Fogarty DG; Groothoff JW; Hoitsma A; Nogier MB; Postorino M; Ravani P; Zurriaga O; Jager KJ; Gansevoort RT; ; ; ; ;
Kidney Int; 2014 Dec; 86(6):1244-52. PubMed ID: 24827775
[TBL] [Abstract][Full Text] [Related]
16. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.
Reule S; Sexton DJ; Solid CA; Chen SC; Collins AJ; Foley RN
Am J Kidney Dis; 2014 Oct; 64(4):592-9. PubMed ID: 25134777
[TBL] [Abstract][Full Text] [Related]
17. Concomitant nephrectomy of massively enlarged kidneys and renal transplantation in autosomal dominant polycystic kidney disease.
Tabibi A; Simforoosh N; Abadpour P; Gholamrezaie HR; Nafar M
Transplant Proc; 2005 Sep; 37(7):2939-40. PubMed ID: 16213267
[TBL] [Abstract][Full Text] [Related]
18. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease.
Reiterová J; Obeidová H; Lenícek M; Stekrová J; Merta M; Maixnerová D; Vítek L; Viklický O; Tesar V
Kidney Blood Press Res; 2008; 31(6):398-403. PubMed ID: 19060482
[TBL] [Abstract][Full Text] [Related]
19. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
20. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.
Younossi ZM; Otgonsuren M; Henry L; Arsalla Z; Stepnaova M; Mishra A; Venkatesan C; Hunt S
J Viral Hepat; 2015 Feb; 22(2):137-45. PubMed ID: 24813350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
